SK282640B6 - Transdermálny terapeutický systém vo forme náplasti - Google Patents
Transdermálny terapeutický systém vo forme náplasti Download PDFInfo
- Publication number
- SK282640B6 SK282640B6 SK338-97A SK33897A SK282640B6 SK 282640 B6 SK282640 B6 SK 282640B6 SK 33897 A SK33897 A SK 33897A SK 282640 B6 SK282640 B6 SK 282640B6
- Authority
- SK
- Slovakia
- Prior art keywords
- active substance
- transdermal therapeutic
- therapeutic system
- scopolamine base
- scopolamine
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 16
- 239000011505 plaster Substances 0.000 title claims abstract description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims abstract description 43
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims abstract description 43
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims abstract description 43
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims abstract description 43
- 229960002646 scopolamine Drugs 0.000 claims abstract description 43
- 239000013543 active substance Substances 0.000 claims abstract description 28
- 239000012528 membrane Substances 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 229920000642 polymer Polymers 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract description 9
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 229940055577 oleyl alcohol Drugs 0.000 claims description 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 4
- BODMYPYTCKYRSP-UHFFFAOYSA-N 1,1-dioctylcyclohexane Chemical compound CCCCCCCCC1(CCCCCCCC)CCCCC1 BODMYPYTCKYRSP-UHFFFAOYSA-N 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 229920005601 base polymer Polymers 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- -1 dioctylcyclohexane Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 8
- 230000001681 protective effect Effects 0.000 abstract description 5
- 150000001252 acrylic acid derivatives Chemical class 0.000 abstract 1
- 239000011888 foil Substances 0.000 abstract 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 16
- 239000000853 adhesive Substances 0.000 description 14
- 230000001070 adhesive effect Effects 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 11
- 229920000058 polyacrylate Polymers 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229920006267 polyester film Polymers 0.000 description 8
- 239000007788 liquid Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XBIUWALDKXACEA-UHFFFAOYSA-N 3-[bis(2,4-dioxopentan-3-yl)alumanyl]pentane-2,4-dione Chemical compound CC(=O)C(C(C)=O)[Al](C(C(C)=O)C(C)=O)C(C(C)=O)C(C)=O XBIUWALDKXACEA-UHFFFAOYSA-N 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940100640 transdermal system Drugs 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001955 cumulated effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 125000005395 methacrylic acid group Chemical class 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Polyurethanes Or Polyureas (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4433004 | 1994-09-16 | ||
| DE4438989A DE4438989C2 (de) | 1994-09-16 | 1994-10-31 | Scopolaminpflaster |
| PCT/EP1995/003555 WO1996008251A1 (de) | 1994-09-16 | 1995-09-09 | Scopolaminpflaster |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK33897A3 SK33897A3 (en) | 1997-09-10 |
| SK282640B6 true SK282640B6 (sk) | 2002-10-08 |
Family
ID=25940173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK338-97A SK282640B6 (sk) | 1994-09-16 | 1995-09-09 | Transdermálny terapeutický systém vo forme náplasti |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5714162A (cs) |
| EP (1) | EP0781134B9 (cs) |
| JP (1) | JP4466977B2 (cs) |
| CN (1) | CN1087938C (cs) |
| AT (1) | ATE262333T1 (cs) |
| AU (1) | AU695698B2 (cs) |
| CA (1) | CA2200189C (cs) |
| CZ (1) | CZ289313B6 (cs) |
| DE (1) | DE59510883D1 (cs) |
| ES (1) | ES2219665T3 (cs) |
| FI (1) | FI118885B (cs) |
| HU (1) | HUT77383A (cs) |
| IL (1) | IL115189A (cs) |
| MX (1) | MX9701968A (cs) |
| MY (1) | MY112477A (cs) |
| NO (1) | NO312496B1 (cs) |
| NZ (1) | NZ292921A (cs) |
| PL (1) | PL182158B1 (cs) |
| SK (1) | SK282640B6 (cs) |
| WO (1) | WO1996008251A1 (cs) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19738643C2 (de) * | 1997-09-04 | 2001-10-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung |
| US6087341A (en) * | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
| US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
| CN101524339A (zh) * | 2001-03-16 | 2009-09-09 | 阿尔扎公司 | 施用芬太尼的经皮贴剂 |
| US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| CN100512806C (zh) * | 2003-04-14 | 2009-07-15 | Lts勒曼治疗系统股份公司 | 具有包含辣椒碱的聚硅氧烷基质的治疗贴剂 |
| AU2004231740A1 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Ofnew York | Desmoglein 4 is a novel gene involved in hair growth |
| CA2557532A1 (en) | 2004-04-23 | 2005-11-10 | Angela M. Christiano | Inhibition of hairless protein mrna |
| FR2884143B1 (fr) * | 2005-04-08 | 2007-06-22 | Millet Innovation Sa | Timbre dermique rechargeable |
| US20070010550A1 (en) * | 2005-07-08 | 2007-01-11 | The Board Of Regents Of The University Of Texas | Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia |
| EP1998756A2 (en) * | 2006-02-27 | 2008-12-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for delivery of amino-functional drugs |
| DE102006028987A1 (de) * | 2006-06-24 | 2007-12-27 | Lts Lohmann Therapie-Systeme Ag | Ultraschallverstärktes transdermales therapeutisches System |
| CN104398496B (zh) * | 2007-10-15 | 2018-03-20 | 阿尔扎公司 | 芬太尼的一天更换一次透皮施用 |
| CN102764342B (zh) * | 2012-07-17 | 2013-12-04 | 陈鼎汉 | 治疗褥疮、糖尿病伤口、烫伤的药膏 |
| EP3943156A4 (en) * | 2019-03-19 | 2023-01-04 | Nobelpharma Co., Ltd. | Medicinal composition having excellent absorption of drug into living body and excellent chemical stability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8104929A (nl) * | 1980-11-12 | 1982-06-01 | Alza Corp | Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan. |
| US5310559A (en) * | 1982-09-01 | 1994-05-10 | Hercon Laboratories Corporation | Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer |
| US4832953A (en) * | 1987-08-13 | 1989-05-23 | Alza Corporation | Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| ES2062093T3 (es) * | 1988-08-02 | 1994-12-16 | Ciba Geigy Ag | Emplasto de varias capas. |
| US5176917A (en) * | 1989-03-15 | 1993-01-05 | Lts Lohmann | Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances |
| DE3908431A1 (de) * | 1989-03-15 | 1990-09-27 | Lohmann Therapie Syst Lts | Transdermales system mit gestufter wirkstoffabgabe und verwendung fuer die lokale oder systemische wirkstoffverabreichung |
| JPH04261119A (ja) * | 1991-02-13 | 1992-09-17 | Lintec Corp | 経皮吸収型貼付剤 |
-
1995
- 1995-01-05 US US08/369,019 patent/US5714162A/en not_active Expired - Lifetime
- 1995-09-06 IL IL11518995A patent/IL115189A/xx not_active IP Right Cessation
- 1995-09-06 MY MYPI95002638A patent/MY112477A/en unknown
- 1995-09-09 DE DE59510883T patent/DE59510883D1/de not_active Expired - Lifetime
- 1995-09-09 SK SK338-97A patent/SK282640B6/sk unknown
- 1995-09-09 WO PCT/EP1995/003555 patent/WO1996008251A1/de active IP Right Grant
- 1995-09-09 AU AU35231/95A patent/AU695698B2/en not_active Ceased
- 1995-09-09 CA CA002200189A patent/CA2200189C/en not_active Expired - Fee Related
- 1995-09-09 CZ CZ1997757A patent/CZ289313B6/cs not_active IP Right Cessation
- 1995-09-09 NZ NZ292921A patent/NZ292921A/en not_active IP Right Cessation
- 1995-09-09 ES ES95932020T patent/ES2219665T3/es not_active Expired - Lifetime
- 1995-09-09 JP JP50989096A patent/JP4466977B2/ja not_active Expired - Lifetime
- 1995-09-09 CN CN95195097A patent/CN1087938C/zh not_active Expired - Fee Related
- 1995-09-09 PL PL95319259A patent/PL182158B1/pl not_active IP Right Cessation
- 1995-09-09 AT AT95932020T patent/ATE262333T1/de not_active IP Right Cessation
- 1995-09-09 HU HU9701966A patent/HUT77383A/hu not_active Application Discontinuation
- 1995-09-09 MX MX9701968A patent/MX9701968A/es not_active IP Right Cessation
- 1995-09-09 EP EP95932020A patent/EP0781134B9/de not_active Expired - Lifetime
-
1997
- 1997-03-14 FI FI971097A patent/FI118885B/fi not_active IP Right Cessation
- 1997-03-14 NO NO19971203A patent/NO312496B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0781134B1 (de) | 2004-03-24 |
| CA2200189A1 (en) | 1996-03-21 |
| NO971203L (no) | 1997-03-14 |
| SK33897A3 (en) | 1997-09-10 |
| IL115189A0 (en) | 1995-12-31 |
| FI971097L (fi) | 1997-03-14 |
| PL319259A1 (en) | 1997-08-04 |
| CZ75797A3 (en) | 1997-07-16 |
| CA2200189C (en) | 2008-06-17 |
| JP4466977B2 (ja) | 2010-05-26 |
| DE59510883D1 (de) | 2004-04-29 |
| FI118885B (fi) | 2008-04-30 |
| EP0781134A1 (de) | 1997-07-02 |
| AU3523195A (en) | 1996-03-29 |
| ATE262333T1 (de) | 2004-04-15 |
| HUT77383A (hu) | 1998-04-28 |
| ES2219665T3 (es) | 2004-12-01 |
| CN1087938C (zh) | 2002-07-24 |
| EP0781134B9 (de) | 2004-09-29 |
| IL115189A (en) | 1999-12-22 |
| NO312496B1 (no) | 2002-05-21 |
| NO971203D0 (no) | 1997-03-14 |
| AU695698B2 (en) | 1998-08-20 |
| PL182158B1 (pl) | 2001-11-30 |
| WO1996008251A1 (de) | 1996-03-21 |
| FI971097A0 (fi) | 1997-03-14 |
| NZ292921A (en) | 1998-09-24 |
| CN1158084A (zh) | 1997-08-27 |
| MX9701968A (es) | 1998-02-28 |
| US5714162A (en) | 1998-02-03 |
| CZ289313B6 (cs) | 2001-12-12 |
| MY112477A (en) | 2001-06-30 |
| JPH10505825A (ja) | 1998-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960005142B1 (ko) | 활성 성분으로서 툴로부테롤을 함유하는 경피성 치료 시스템 | |
| AU678237B2 (en) | Active substance-containing plaster | |
| US4849226A (en) | Method for increasing oxygen supply by administering vasodilator | |
| US20200206148A1 (en) | Transdermal Therapeutic System with Fentanyl or Related Substances | |
| US20040057985A1 (en) | Transdermal therapeutic system comprising the active ingredient oxybutynin | |
| EP1637170A1 (en) | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures | |
| SK282640B6 (sk) | Transdermálny terapeutický systém vo forme náplasti | |
| JP2000517343A (ja) | 医薬の塩を経皮送達するための感圧接着剤マトリックスパッチ | |
| KR20010036685A (ko) | 펜타닐을 함유하는 매트릭스형 경피투여제 | |
| MX2010012989A (es) | Sistema de suministro de farmaco transdermico estabilizado. | |
| KR100511492B1 (ko) | 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제 | |
| KR100473677B1 (ko) | 물리적 특성이 향상된 폴리아크릴레이트 매트릭스를 구비한 경피 또는 국소 플래스터 시스템 | |
| JP2003520191A (ja) | 薬物の親水性塩類を含有する感圧接着剤マトリックスパッチの製造方法 | |
| JP3014188B2 (ja) | アクリル系ゲル材およびアクリル系ゲル製剤 | |
| US4812313A (en) | Method for lessening the incidence of anginal attacks | |
| CN102834092A (zh) | 抗痴呆药物的经皮吸收制剂 | |
| SK3052000A3 (en) | Transdermal therapeutic system containing the active substance scopolamine base | |
| KR20060018207A (ko) | 툴로부테롤 함유 패치 | |
| KR100439659B1 (ko) | 툴로부테롤을 함유하는 경피흡수용 패취제 | |
| KR950013448B1 (ko) | 경피 투여형 약물용 첩포(貼布)제 | |
| KR100394830B1 (ko) | 스코폴아민패치 | |
| JPH07116025B2 (ja) | 貼付剤 | |
| EP1196151B1 (en) | Transdermal therapeutic system for administering a calcium antagonist | |
| US20030175330A1 (en) | Transdermal therapeutical system with a reduced tendency of the active substance to crystallize | |
| JP4617069B2 (ja) | 貼付剤 |